Lactobacillus casei PXN 37 and Reduced Inflammation

Across 3 studies, all reported beneficial effects, with two meta-analyses (total n=703) finding statistically significant reductions in inflammatory markers such as IL-6, TNFα, and hs-CRP. The predominant effect size is moderate, and the evidence primarily comes from patients with autoimmune and neurodegenerative diseases, though one study showed effects only in depressed patients with somatic comorbidities. No consistent dose or duration was reported across studies.

• Studied populations: patients with autoimmune diseases, depressed patients with somatic comorbidities, patients with neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis, mild cognitive impairment)

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Additionally, the third study is a non-systematic review with no sample size or significance reported, contributing little confirmatory weight.